Premium
A proteomic approach identifies plasma proteins correlated with vitamin B6 in Nepalese children (804.14)
Author(s) -
Yakub Mohsin,
Schulze Kerry,
Cole Robert,
Christian Parul,
Betz Joshua,
Ruczinski Ingo,
Yager James,
Wu Lee,
Groopman John,
West Keith
Publication year - 2014
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.28.1_supplement.804.14
Subject(s) - proteome , population , pyridoxal , chemistry , blood proteins , biochemistry , biology , enzyme , medicine , environmental health
Vitamin B6 is a coenzyme for >140 distinct enzymes involved in amino acid metabolism. In the plains of Nepal, we have reported 43% of children age 6‐8 years of age to be B6 deficient (pyridoxal‐5’‐phosphate, PLP <20nmol/L), revealing a public health problem. This study identified differentially abundant plasma proteins in relation to B6 status in 500 6‐8 yr old Nepalese children that represent possible B6 biomarkers with the potential to predict B6 status. Plasma PLP concentration was analyzed by HPLC, and relative abundance of plasma proteins by isobaric tags for relative and absolute quantification (iTRAQ) tandem mass spectrometry. A total of 87 proteins were associated with PLP (for all, q<0.1, p<0.008), defining a plasma B6 proteome: 39 and 48 were positively and negatively correlated (r from 0.51 to 0.29 and ‐0.56 to ‐0.21) with PLP, respectively. Identified proteins are involved in numerous metabolic pathways, including cell proliferation, proteolysis, adhesion, acute phase reaction, coagulation and transport. Linear mixed effects analysis estimated ~60% of the variance (R²) in plasma PLP could be estimated by the relative abundance of 5 proteins (complement 9, cyclin D‐type binding‐protein 1, dynein, axonemal, heavy chain 10, leucine rich repeat containing 47, and NOP2/Sun domain family, member 6). A predictive plasma PLP proteome may exist for assessing population B6 status. Grant Funding Source : Supported by Bill and Melinda Gates Foundation Grants 614 and 5241